Profile data is unavailable for this security.
About the company
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
- Revenue in USD (TTM)51.13m
- Net income in USD-224.80m
- Incorporated2018
- Employees647.00
- LocationAutolus Therapeutics PLCThe Mediaworks, 191 Wood LaneLONDON W12 7FPUnited KingdomGBR
- Phone+44 203 829 6230
- Websitehttps://www.autolus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abeona Therapeutics Inc | 400.00k | 82.35m | 271.50m | 136.00 | 4.53 | 1.53 | 3.21 | 678.75 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Evolus Inc | 285.82m | -58.56m | 278.73m | 329.00 | -- | -- | -- | 0.9752 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Fennec Pharmaceuticals Inc | 38.79m | -6.94m | 287.57m | 36.00 | -- | -- | -- | 7.41 | -0.2524 | -0.2524 | 1.41 | -0.1601 | 0.7171 | 1.48 | 2.41 | -- | -12.83 | -55.15 | -15.26 | -64.98 | 93.12 | -- | -17.89 | -107.31 | 4.44 | -2.44 | 1.33 | -- | 123.69 | -- | 97.28 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 33.98m | -95.10m | 298.16m | 143.00 | -- | 1.39 | -- | 8.77 | -10.50 | -10.50 | 2.94 | 2.45 | 0.1989 | 1.75 | 25.37 | 237,615.40 | -55.66 | -55.04 | -65.82 | -63.45 | 83.24 | -- | -279.86 | -6,897.81 | 5.48 | -19.26 | 0.5525 | -- | -- | -- | 62.98 | -- | 111.28 | -- |
| AC Immune SA | 5.70m | -93.66m | 300.23m | 133.00 | -- | 3.69 | -- | 52.70 | -0.932 | -0.932 | 0.0567 | 0.8104 | 0.021 | -- | 0.3392 | 42,835.79 | -34.57 | -27.41 | -66.37 | -30.60 | -- | -- | -1,643.94 | -505.58 | -- | -- | 0.0695 | -- | 84.51 | -24.38 | 6.12 | -- | -21.11 | -- |
| Akebia Therapeutics Inc | 225.07m | -15.91m | 321.09m | 181.00 | -- | 7.72 | -- | 1.43 | -0.0761 | -0.0761 | 0.8951 | 0.1568 | 0.7879 | 2.08 | 4.57 | 1,243,486.00 | -5.57 | -38.92 | -8.55 | -61.07 | 81.89 | 71.93 | -7.07 | -76.49 | 1.80 | 0.7147 | 0.8219 | -- | -17.70 | -13.72 | -33.67 | -- | -65.40 | -- |
| Puma Biotechnology Inc | 212.00m | 36.98m | 343.67m | 172.00 | 9.20 | 2.98 | 7.14 | 1.62 | 0.7414 | 0.7414 | 4.23 | 2.29 | 1.00 | 8.06 | 4.81 | 1,232,529.00 | 17.46 | -3.25 | 32.09 | -5.70 | 76.91 | 75.67 | 17.44 | -3.18 | 1.62 | 8.84 | 0.2263 | -- | -2.19 | -3.28 | 40.23 | -- | -28.80 | -- |
| Autolus Therapeutics PLC (ADR) | 51.13m | -224.80m | 372.60m | 647.00 | -- | -- | -- | 7.29 | -0.8447 | -0.8447 | 0.1921 | -- | 0.0687 | -- | 2.86 | 79,023.19 | -30.19 | -40.88 | -33.21 | -45.08 | -61.21 | -- | -439.68 | -3,879.20 | 5.86 | -- | 0.4942 | -- | 496.00 | 28.33 | -5.89 | -- | 13.28 | -- |
| Enanta Pharmaceuticals Inc | 66.98m | -71.54m | 401.92m | 120.00 | -- | 3.17 | -- | 6.00 | -3.20 | -3.20 | 2.89 | 4.36 | 0.1975 | -- | 8.26 | 558,166.70 | -21.10 | -26.15 | -24.48 | -29.36 | -- | -- | -106.80 | -134.68 | -- | -- | 0.5181 | -- | -3.42 | -11.81 | 29.43 | -- | 54.92 | -- |
| Invivyd Inc | 50.04m | -59.86m | 439.90m | 99.00 | -- | 3.59 | -- | 8.79 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Aquestive Therapeutics Inc | 43.40m | -68.98m | 445.31m | 142.00 | -- | -- | -- | 10.26 | -0.7031 | -0.7031 | 0.4377 | -0.0338 | 0.3173 | 2.31 | 4.15 | 305,612.70 | -50.44 | -70.67 | -59.26 | -110.99 | 60.28 | 65.92 | -158.95 | -92.17 | 5.62 | -7.42 | 1.03 | -- | 13.80 | 1.82 | -460.83 | -- | -24.84 | -- |
| Eton Pharmaceuticals Inc | 70.32m | -6.68m | 457.78m | 31.00 | -- | 19.79 | -- | 6.51 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Elite Pharmaceuticals Inc | 122.89m | 13.92m | 472.78m | 68.00 | 36.07 | 7.67 | 30.39 | 3.85 | 0.0122 | 0.0122 | 0.1131 | 0.0574 | 1.20 | 3.60 | 3.94 | 1,807,255.00 | 13.55 | 13.18 | 15.31 | 16.01 | 52.66 | 47.19 | 11.33 | 13.97 | 6.34 | 2.37 | 0.0681 | 0.00 | 48.42 | 36.10 | -121.46 | -- | 135.38 | -- |
| Zevra Therapeutics Inc | 84.39m | 35.33m | 478.53m | 59.00 | 14.38 | 3.59 | 11.77 | 5.67 | 0.591 | 0.591 | 1.54 | 2.37 | 0.3656 | -- | 6.85 | 1,430,305.00 | 15.30 | -37.95 | 17.62 | -48.83 | 93.88 | -- | 41.86 | -193.51 | 8.57 | -9.57 | 0.3153 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
Data as of Feb 13 2026. Currency figures normalised to Autolus Therapeutics PLC's reporting currency: US Dollar USD
40.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| MAK Capital One LLCas of 01 Dec 2025 | 26.89m | 10.10% |
| Syncona Investment Management Ltd.as of 31 Dec 2025 | 16.64m | 6.25% |
| Armistice Capital LLCas of 30 Sep 2025 | 15.60m | 5.86% |
| Qatar Investment Authority (Investment Management)as of 01 Mar 2025 | 15.00m | 5.64% |
| Tetragon Partners UK LLPas of 30 Sep 2025 | 9.50m | 3.57% |
| Schroder Investment Management Ltd.as of 31 Dec 2025 | 9.49m | 3.57% |
| Citadel Securities LLCas of 30 Sep 2025 | 6.04m | 2.27% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2025 | 3.36m | 1.26% |
| Laurion Capital Management LPas of 31 Dec 2025 | 3.32m | 1.25% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 3.11m | 1.17% |
More ▼
Data from 30 Sep 2025 - 02 Feb 2026Source: FactSet Research Systems Inc.
